---
title: "Medicus Pharma’s SkinJect SPAC and CD228V ADC Catalysts Support Buy Rating; $15 Price Target Maintained"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305071960.md"
description: "Maxim Group analyst Jason McCarthy maintained a Buy rating on Medicus Pharma with a $15 price target. The decision is supported by the proposed SkinJect SPAC transaction, which offers capital-efficient funding while allowing Medicus to retain majority ownership. Additionally, the CD228V ADC program benefits from an active IND and Pfizer support, with melanoma trial data expected in Q1 2027. A redesigned Teverelix study may also attract development partners by reducing costs."
datetime: "2026-11-10T21:45:32.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305071960.md)
  - [en](https://longbridge.com/en/news/305071960.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305071960.md)
generator: "portal-rs"
---

# Medicus Pharma’s SkinJect SPAC and CD228V ADC Catalysts Support Buy Rating; $15 Price Target Maintained

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Medicus Pharma Ltd and keeping the price target at $15.00.

Jason McCarthy has given his Buy rating due to a combination of factors, including Medicus Pharma’s proposed SkinJect SPAC transaction at an estimated $135 million pre-money valuation. The deal could create an independent source of funding for SkinJect while allowing Medicus to retain majority ownership and participate in the asset’s future upside. This structure supports the company’s capital-efficient strategy and may let it direct more resources toward its leading development program.  
Medicus’ CD228V ADC offers a relatively advanced starting point through an active IND, previous clinical work, manufacturing inventory, and development support from Pfizer, with a melanoma trial restart and initial data expected in 1Q27. Teverelix may also attract a development partner after a redesigned study reduced the planned enrollment from about 1,500 to roughly 608 patients, potentially lowering costs. Against these catalysts and opportunities for strategic transactions, McCarthy maintained the $15 price target and assigned the stock a Buy rating.

### Related Stocks

- [MDCX.US](https://longbridge.com/en/quote/MDCX.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

- [Medicus Pharma Raises About $1.25 Million in Insider-Led Private Placements](https://longbridge.com/en/news/306122284.md)
- [Medicus Pharma Raises $1.25 Million in CEO-Led Private Placement](https://longbridge.com/en/news/305671056.md)
- [Medicus Pharma plans SkinJect combination with undisclosed SPAC](https://longbridge.com/en/news/304285262.md)
- [Medicus Pharma Unveils Capital Strategy Centered On Novel Cancer Pipeline](https://longbridge.com/en/news/304852138.md)
- [Nasdaq (NDAQ) Just Gave Investors Something To Think About](https://longbridge.com/en/news/306370324.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**